Baird Reiterates an 'Outperform' on Incyte (INCY) following Confirmatory Phase 3 Details for Ruxolitinib
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $120.16 -0.3%
Rating Summary:
17 Buy, 17 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
17 Buy, 17 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Baird reiterates an 'Outperform' on Incyte (NASDAQ: INCY), PT $24.
Baird analyst said, "Continue to recommend purchase following confirmatory Phase 3 details for ruxolitinib (‘424). We saw no major surprises on efficacy or safety, there was a thinly veiled shot fired across the competitor’s bow, and an impartial discussion session was very supportive. Our thesis remains intact, including positive views on INCY’s upcoming regulatory and commercial pieces, and a belief the competitor overhang will continue to lift as the year goes on."
"Myeloproliferative disease opportunity could accelerate the path to profitability...Exceptionally broad and deep mid-stage pipeline offers many shots on goal in attractive areas...Excellent catalyst flow could drive meaningful advances in the stock."
For more ratings news on Incyte click here and for the rating history of Incyte click here.
Shares of Incyte closed at $16.51 yesterday.
Baird analyst said, "Continue to recommend purchase following confirmatory Phase 3 details for ruxolitinib (‘424). We saw no major surprises on efficacy or safety, there was a thinly veiled shot fired across the competitor’s bow, and an impartial discussion session was very supportive. Our thesis remains intact, including positive views on INCY’s upcoming regulatory and commercial pieces, and a belief the competitor overhang will continue to lift as the year goes on."
"Myeloproliferative disease opportunity could accelerate the path to profitability...Exceptionally broad and deep mid-stage pipeline offers many shots on goal in attractive areas...Excellent catalyst flow could drive meaningful advances in the stock."
For more ratings news on Incyte click here and for the rating history of Incyte click here.
Shares of Incyte closed at $16.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Fiserv (FISV) PT Lowered to $60 at Freedom Broker
- Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald
- McGraw Hill (MH) PT Raised to $15 at UBS
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
